eCite Digital Repository

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

Citation

Olver, IN and Grimison, P and Chatfield, M and Stockler, MR and Toner, GC and Gebski, V and Harrup, R and Underhill, C and Kichenadasse, G and Singhal, N and Davis, ID and Boland, A and McDonald, A and Thomson, D, Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy, Supportive Care in Cancer, 21, (6) pp. 1561-1568. ISSN 0941-4355 (2013) [Refereed Article]

Copyright Statement

Copyright 2013 Springer

DOI: doi:10.1007/s00520-012-1696-0

Abstract

Purpose: The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy.

Methods: In a single-arm, open-label, multi-center, phase 2 trial, chemo-naive patients received aprepitant 125 mg PO (per oral) on day 1 and 80 mg PO on days 2 to 7, a 5HT3 receptor antagonist on days 1 to 5, and dexamethasone 8 mg on days 1 to 8. The primary endpoint was no emesis (vomiting or dry retching) during days 1 to 7 of cycle 1.

Results: Fifty patients were recruited. For cycle 1, proportions reporting no emesis on day 1, no emesis on days 1 to 7, no nausea on day 1, and no nausea on days 1 to 7 were 96, 82, 71, and 27 %, respectively. The efficacy was maintained in all cycles with over 80 % of patients reporting no emesis on any given day of any given cycle. Emesis was more common on days 4 to 7 (68 % episodes) than on days 1 to 3 (32 % episodes). Over any 24-h period, 49 % of patients with emesis reported no more than two episodes, and 62 % of patients with nausea reported intensity as 3 or less on a scale from 0 to 10. There were no unexpected or serious adverse events reported.

Conclusion: Adding 7 days of aprepitant to a 5HT3 receptor antagonist and dexamethasone effectively controlled acute and delayed emesis with 5-day cisplatin regimens. Days of nausea were more common than days of vomiting.

Item Details

Item Type:Refereed Article
Keywords:aprepitant, dexamethasone, 5Hydroxytryptamine3 receptor antagonist, 5-day cisplatin, antiemetic, germcell tumors
Research Division:Medical and Health Sciences
Research Group:Oncology and Carcinogenesis
Research Field:Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cancer and Related Disorders
Author:Harrup, R (Dr Rosemary Harrup)
ID Code:89205
Year Published:2013
Web of Science® Times Cited:12
Deposited By:Medicine (Discipline)
Deposited On:2014-02-26
Last Modified:2014-05-16
Downloads:0

Repository Staff Only: item control page